Fig. 1: TCGA database analysis and CD8+ and CD103 + T cells in clinical specimens of pancreatic cancer. | British Journal of Cancer

Fig. 1: TCGA database analysis and CD8+ and CD103 + T cells in clinical specimens of pancreatic cancer.

From: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus

Fig. 1

a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database (n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers (n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in (e). Scale bar, 200 µm. f, g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups (n = 3) (f), and between poor and good prognosis groups and between upfront and NAC groups (n = 6) (g). h, i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups (n = 3) (h), and between poor and good prognosis groups and between upfront and NAC groups (n = 6) (i). j, k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups (n = 3) (j), and between poor and good prognosis groups and between upfront and NAC groups (n = 6) (k). *P < 0.05, **P < 0.005, ***P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.

Back to article page